During the past decade, Japanese Foundation for Cancer Research conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 3 clinical trials were completed, i.e. on average, 17.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Japanese Foundation for Cancer Research" #1 sponsor was "Loxo Oncology, Inc." with 7 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Pfizer" with 5 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Kyowa Kirin, Inc." with 2 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Japanese Foundation for Cancer Research" #1 collaborator was "Eli Lilly and Company" with 8 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator and "UCB Pharma" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Japanese Foundation for Cancer Research" are "Breast Neoplasms" (2 trials), "Chronic Lymphocytic Leukemia" (2 trials), "Lymphoma" (2 trials), "Medullary Thyroid Cancer" (2 trials) and "Neoplasms" (2 trials). Many other conditions were trialed in "Japanese Foundation for Cancer Research" in a lesser frequency.

Most popular intervention types in "Japanese Foundation for Cancer Research" are "Drug" (20 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Selpercatinib" (3 trials), "BI 3011441" (2 trials), "Cetuximab" (2 trials), "Inotuzumab Ozogamicin (CMC-544)" (2 trials) and "Pemetrexed" (2 trials). Other intervention names were less common.

The vast majority of trials in "Japanese Foundation for Cancer Research" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Japanese Foundation for Cancer Research". undefined are not yet recruiting, 12 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Japanese Foundation for Cancer Research, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Japanese Foundation for Cancer Research, 6 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Japanese Foundation for Cancer Research has several departments that took part in Clinical trials: "Cancer Institute Hospital" - 7 trials, "The Cancer Institute Hospital of JFCR" - 207 trials, "The Cancer Inst. Hosp. of JFCR; Breast Oncology Center" - 5 trials